Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$3 Mln
Revenue (TTM)
$27 Mln
Net Profit (TTM)
$0 Mln
ROE
-10.9 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
11.2
Industry P/E
24.51
EV/EBITDA
0.1
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-3.2
Face value
--
Shares outstanding
20,548,273
CFO
$-167.54 Mln
EBITDA
$-173.46 Mln
Net Profit
$-299.20 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
CASI Pharmaceuticals (CASI)
| -83.2 | -81.1 | -81.0 | -93.6 | -56.5 | -63.7 | -37.0 |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|
|
CASI Pharmaceuticals (CASI)
| -70.0 | -60.2 | 300.0 | -72.9 | -4.5 | -23.1 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
CASI Pharmaceuticals (CASI)
|
0.1 | 3.2 | 26.9 | -49.4 | -78.3 | -- | -- | 11.2 |
| 9.2 | 2,179.2 | 510.2 | 146.9 | 37.2 | 35.6 | 15.5 | 4.6 | |
| 12.5 | 3,812.0 | 3,018.8 | 72.1 | 12.6 | -80 | 54.3 | 86.1 | |
| 168.5 | 8,210.1 | 638.5 | -183.2 | -27.4 | -252.1 | -- | 92.9 | |
| 73.2 | 13,446.3 | 502.1 | -729.3 | -125.8 | 41.2 | -- | 123.7 | |
| 42.5 | 4,055.0 | 761.4 | 99.7 | 7.3 | 15 | 46.5 | 5.7 | |
| 13.3 | 11,237.7 | 345,831.0 | 56,586.0 | 21.5 | 15.8 | 18.7 | 2.9 | |
| 23.1 | 11,653.6 | 4,715.0 | -232.0 | 0.9 | -3.7 | -- | 1.8 | |
| 8.2 | 7,645.3 | 7,227.1 | 386.1 | 16.6 | 6.9 | 13.8 | 0.9 | |
| 199.6 | 3,841.5 | 268.1 | 124.5 | 60.0 | 13.5 | 31.5 | 4.0 |
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of... melphalan for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. The company's hematology/oncology assets in pipeline include CNCT19, an autologous CD19 CAR-T investigative product; BI-1206, an novel anti-Fc"RIIB antibody for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. It has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China. Address: 1701-1702, China Central Office Tower 1, Beijing, China, 100025 Read more
Chairman & CEO
Dr. Wei-Wu He Ph.D.
Chairman & CEO
Dr. Wei-Wu He Ph.D.
Headquarters
Beijing
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of CASI Pharmaceuticals Inc (CASI) is $0.14 (NASDAQ) as of 24-Mar-2026 09:30 EDT. CASI Pharmaceuticals Inc (CASI) has given a return of -56.45% in the last 3 years.
Since, TTM earnings of CASI Pharmaceuticals Inc (CASI) is negative, P/E ratio is not available.
The P/B ratio of CASI Pharmaceuticals Inc (CASI) is 11.21 times as on 24-Mar-2026, a 98 premium to its peers’ median range of 5.66 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
-1.12
|
23.69
|
|
2023
|
-3.56
|
3.96
|
|
2022
|
-0.60
|
0.55
|
|
2021
|
-0.30
|
0.13
|
|
2020
|
-0.72
|
0.43
|
The 52-week high and low of CASI Pharmaceuticals Inc (CASI) are Rs 3.09 and Rs 0.14 as of 03-Apr-2026.
CASI Pharmaceuticals Inc (CASI) has a market capitalisation of $ 3 Mln as on 24-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in CASI Pharmaceuticals Inc (CASI), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.10
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.